Viramal to Present at the 18th Annual BIO CEO & Investor Conferencehttps://www.viramal.com/wp-content/themes/corpus/images/empty/thumbnail.jpg 150 150 Administrator Administrator https://secure.gravatar.com/avatar/f9ef45671a5f38bfb74c48694d0cccbe?s=96&d=mm&r=g
NEW YORK, February 3, 2016 /PRNewswire/ — Viramal, (“the Company”), an emerging specialty pharmaceutical company developing therapeutics that improve the quality of women’s health, today announced that the Company’s CEO, Oliver Bates, will present at the 18th Annual BIO CEO & Investor Conference. The presentation will take place on Monday, February 8, 2016 at 4:00 p.m. ET in the Park North room at The Waldorf Astoria in New York City. Mr. Bates will be joined by Viramal’s Chairman, William Bologna.
Mr. Bates will outline Viramal’s robust women’s health clinical development pipeline and strategy to produce a step change in existing female healthcare products, as well as develop innovative products that target unmet therapeutic areas, by leveraging novel platform delivery technologies that offer greater safety and efficacy. The presentation will be available in the “News” section of the Company’s website, www.viramal.com.
To schedule a meeting with Viramal’s management team at the conference, use the BIO CEO one-on-one meeting portal for registered participants or contact Katja Buhrer in the Investor Relations department at firstname.lastname@example.org.
Viramal is an emerging specialty pharmaceutical company focused on the development of therapeutics that improve the quality of women’s health. The Company’s well-recognized management team has pioneered market-leading products in fertility and female sexual health, having successfully developed and licensed Crinone®, Replens® and RepHresh®. Viramal produces a step change in these existing products, as well as develops innovative products that target unmet therapeutic areas, by leveraging novel platform delivery technologies that offer greater safety, efficacy and patient acceptability with far fewer side effects. The Company’s robust women’s health clinical development pipeline includes treatments for fertility, menopausal hormone therapy, contraception and sexual health. In addition, Viramal’s only male product, TestoCream (transdermal delivery of testosterone), has shown 81% success in a partially completed Phase III study. Please visit www.viramal.com for more information.
About the BIO CEO & Investor Conference
Now in its eighteenth year, the BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Each year this conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference will be held February 8-9, 2016 at the Waldorf Astoria in New York City.
MBS Value Partners